1 reply to this topic

[ImmInst]

Regenicin, Inc. (OTCBB: RGIN), a biotechnology company specializing in the development of regenerative cell therapies, similar to companies like Osiris Therapeutics, Inc. (Nasdaq: OSIR) and Geron Corporation (Nasdaq: GERN), is seeking to become the first regenerative medicine company to introduce a commercial product into a multi-billion dollar market.

Regenicin, Inc., a biotechnology company specializing in the development of regenerative cell therapies, is seeking to become the first regenerative medicine company to introduce a commercial product into a multi-billion dollar market. With an all-star management team and solid clinical data supporting its products, investors may want to keep a close eye on this emerging biotechnology company over the coming year.

View the full article

[caliban]

Not life extension relevant at this stage.

is seeking to become the first regenerative medicine company to introduce a commercial product into a multi-billion dollar market.

Meaning... PermaDerm™?

The flagship technology is the world’s first autologous full thickness skin product, PermaDerm, that uses the patients’ own skin. While other products ranging from cadavers to synthetics may offer some solutions, the company’s product (the patients own full thickness skin) can help dramatically accelerate wound healing, preserve a natural look, and requires little additional physician training.

Hype is nice, but you may want to be respectful to the intelligence and experience of investors in this sector.

Some context please:
http://www.intercyte...istofregmed.pdf